[Active surveillance of prostate cancer]

The aim of active surveillance (AS) is to avoid overtreatment of clinically insignificant prostate cancer (PCa). It is now strongly recommended for patients diagnosed with localized low-risk PCa. Additionally, it can be considered for selected patients with localized PCa in the International Society of Urological Pathology (ISUP) group 2, provided patients have a favorable risk profile. This profile is histopathologically characterized by the presence of a low percentage of Gleason pattern 4 and the absence of cribriform or intraductal components. The role of magnetic resonance imaging (MRI), including the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations on monitoring is increasing. It is crucial to adhere to defined intervals for prostate-specific antigen (PSA) level checks, repeat biopsies, MRI and further targeted and systematic biopsies under AS. The MRI of the prostate (according to the current recommendations as multiparametric MRI, mpMRI), as a noninvasive diagnostic tool, has the potential to be used as a decision aid for determining the need for repeated biopsies during AS. As the trigger for deciding for an active treatment PSA progression alone is not sufficient but there must be a biopsy-confirmed tumor progression with an upgrading. This continuing medical education (CME) article summarizes the current indications, procedures and discontinuation criteria for AS based on the latest evidence and an adaptation to international guidelines.